Zota Health Care: CRISIL Monitoring Report for Preferential Issue Funds (Q4FY26)
Zota Health Care Limited submitted its Monitoring Agency Report for Q4FY26, confirming full utilization of ₹123.41 crore raised via Preferential Issue. Funds were used for DAVAINDIA project expansion, working capital, and general corporate purposes. Related party transactions for inventory purchase were conducted.
This is a standard compliance report detailing the utilization of funds from a past preferential issue. It does not contain new financial performance data, strategic announcements, or significant corporate actions that would materially impact the company's stock or operations.
The announcement is a routine regulatory filing providing an update on fund utilization. It confirms that funds were utilized as planned, with no significant deviations or issues highlighted.
Zota Health Care Limited has submitted the Monitoring Agency Report issued by CRISIL Ratings Limited for the quarter ended March 31, 2026. This report pertains to the utilization of funds raised through a Preferential Issue, as approved by the Board and members in January and February 2025.
The Monitoring Agency Report confirms that the utilization of proceeds is in line with the disclosures in the Offer Document. The total issue size was ₹123.41 crore. The allocated funds were for the expansion of the ‘DAVAINDIA’ Project (FOFO and COCO), working capital requirements, and general corporate purposes.
As of March 31, 2026, the company has fully utilized the proceeds amounting to ₹123.41 crore. The expansion of the ‘DAVAINDIA’ Project - FOFO and working capital requirements were fully utilized by September 30, 2025. The ‘DAVAINDIA’ Project - COCO saw utilization towards vendor payments for civil work and inventory procurement. General corporate purposes funds were fully utilized by December 31, 2025.
During the quarter, the company undertook related party transactions with its wholly-owned subsidiary, M/s Dava India Health Care Limited, for inventory purchase amounting to ₹11.08 crore, in line with prior Audit Committee approval. The report also notes a reduction in the original cost of the expansion projects due to a partial non-subscription by one of the proposed allottees. The Audit Committee and Board of Directors reviewed this report via circular resolutions passed on May 13, 2026.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.